Rui Sang

Rui Sang

Auto-generated profile, based on publicly available information

Rui Sang

University of New South Wales

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
FDFei Deng
Fei Deng
YLYi Li
Yi Li
BYBiyao Yang
Biyao Yang
RSRui Sang
Rui Sang
WDWei Deng
Wei Deng
EGEwa Goldys
Ewa Goldys
Control of CRISPR/Cas12a trans-cleavage is crucial for biosensor development. Here, we show that small circular DNA nanostructures which partially match guide RNA sequences only minimally activate Cas12a ribonucleoproteins. However, linearizing these structures restores activation. Building on this finding, an Autocatalytic Cas12a Circular DNA Amplification Reaction (AutoCAR) system is established which allows a single nucleic acid target to activate multiple ribonucleoproteins, and greatly increases the achievable reporter cleavage rates per target. A rate-equation-based model explains the observed near-exponential rate trends. Autocatalysis is also sustained with DNA nanostructures modified with fluorophore-quencher pairs achieving 1 aM level (<1 copy/μL) DNA detection (106 times improvement), without additional amplification, within 15 min, at room temperature. The detection range is tuneable, spanning 3 to 11 orders of magnitude. We demonstrate 1 aM level detection of SNP mutations in circulating tumor DNA from blood plasma, genomic DNA (H. Pylori) and RNA (SARS-CoV-2) without reverse transcription as well as colorimetric lateral flow tests of cancer mutations with ~100 aM sensitivity.

1 June 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
RSRui Sang
Rui Sang
BSBradley Stratton
Bradley Stratton
AEAlexander Engel
Alexander Engel
WDWei Deng
Wei Deng

31 August 2025 in Acta Biomaterialia
Verified
Journal Article
Open access
KZKainat Zahra
Kainat Zahra
FDFei Deng
Fei Deng
WDWei Deng
Wei Deng
RSRui Sang
Rui Sang
Breast cancer remains one of the leading causes of cancer-related mortality worldwide, with treatment resistance and recurrence posing significant challenges to conventional therapies such as chemotherapy, surgery, and radiotherapy. Photosensitiser-assisted treatment strategies, particularly photodynamic therapy (PDT), have emerged as a promising alternative for breast cancer due to its targeted nature and minimally invasive approach. This review provides an overview of PDT as a treatment strategy for breast cancer. We begin by discussing the current therapeutic approaches and their limitations in breast cancer management. We then examine the principles and mechanisms underlying PDT, along with various delivery systems employed to enhance its efficacy, including liposomes, extracellular vesicles, gold nanoparticles and lipid-polymer hybrid nanoparticles. Furthermore, we highlight the recent advances in PDT-based combination therapies and their progress in clinical development. Finally, we identify the key remaining challenges and outline potential future research directions with a particular focus on AI integration, to improve therapeutic outcomes for breast cancer patients. STATEMENT OF SIGNIFICANCE: Conventional treatments for breast cancer severely affect the therapeutic effects, particularly for aggressive and treatment-resistant subtypes. Photodynamic therapy (PDT) has emerged as a promising, minimally invasive alternative that enables selective tumour targeting. In the past three years, several reviews in this area have been published focusing on inorganic nanoparticles-based PDT and preclinical studies, which is a fairly narrow focus in the field of PDT for breast cancer. Our review addresses this gap by summarising the most recent developments in both preclinical and clinical applications of PDT for breast cancer, with a particular focus on its use in combination with other therapeutic modalities. We also explore future directions, including the integration of artificial intelligence to enhance treatment precision. This timely and broad-scope review is expected to attract wide interest from researchers, clinicians and industry stakeholders aiming to advance breast cancer therapies.

9 February 2018 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
HZHailong Zhang
Hailong Zhang
LJLi Jing
Li Jing
YZYang Zheng
Yang Zheng
RSRui Sang
Rui Sang
YZYi Zhao
Yi Zhao
YWYong Wu
Yong Wu

28 February 2025 in Microchemical Journal
Verified
Journal Article
Closed access
LPLulu Pan
Lulu Pan
YMYongcheng Ma
Yongcheng Ma
RSRui Sang
Rui Sang
XLXia Lu
Xia Lu
XFXiaxia Fan
Xiaxia Fan
FDFei Deng
Fei Deng

12 May 2025 in EBioMedicine
Verified
Journal Article
Open access
RSRui Sang
Rui Sang
SNSheri Nixdorf
Sheri Nixdorf
THTzongtyng Hung
Tzongtyng Hung
CPCarl Power
Carl Power
FDFei Deng
Fei Deng
WDWei Deng
Wei Deng
Rectal cancer is a leading cause of cancer-related mortality worldwide. The recurrence of locally advanced rectal cancer (LARC), particularly in cases involving lymph node-positive tumours, remains a critical challenge in rectal cancer management. In this study, a therapeutic strategy, radiation-activated photodynamic therapy (RA-PDT), for the treatment of LARC with lymph node-positive tumours was developed and evaluated. RA-PDT was achieved by using a lipid-polymer hybrid nanoplatform loaded with verteporfin (VP) and functionalised with folic acid (FA) as a targeting molecule. Upon receiving a single 4 Gy fraction of radiation, VP was effectively activated, generating sufficient reactive oxygen species (ROS) to induce cancer cell death-however surrounding tissue was less affected and was spared. The efficacy of this strategy was assessed through in vitro cytotoxicity studies in HCT116 cells, as well as in orthotopic and subcutaneous mouse models. In vivo lymph node tumour progression was also evaluated. RA-PDT effectively generated ROS following 4 Gy irradiation and exhibited significant cytotoxicity in HCT116 cells. In vivo, this strategy largely inhibited primary tumour growth in both orthotopic and subcutaneous mouse models while also suppressing lymph node tumour progression. Surrounding tissues were minimally affected, highlighting the precision and safety of this approach. RA-PDT demonstrates potential as a safe therapeutic strategy for LARC, paving the way for its clinical translation. This study was supported by the Australian National Health and Medical Research Council (GNT1181889), fellowship award (2019/CDF1013) from Cancer Institute NSW, Australia, the Australian Research Council Centre of Excellence for Nanoscale Biophotonics (CE140100003), UNSW SHARP funding, project grant from National Foundation for Medical Research and Innovation, Australia, International Research Training Program Scholarship (IRTP) from Australian Government, PhD Research Scholar Award from Sydney Vital Translational Cancer Research, and Translational Cancer Research Network PhD Scholarship Top-up award.